Cancer is a continuing public health concern with well over one million new diagnoses annually in the US alone.  Ultimately, cancer kills one in four Americans, and is second only to cardiovascular disease as the most common cause of death. Treatment for most cancers is insufficient despite early detection methods. As a result, there is an urgent need for novel anti-cancer agents. Biomodels provides a wide spectrum of in vivo and in vitro preclinical oncology models, designed specifically to enable the successful translation of novel anticancer drugs, biologics, and devices into human clinical trials. 

As members of the American Association for Cancer Research (AACR), our Oncology Group has presented their own work at AACR-sponsored conferences, published in top journals, and have made significant contributions to translational cancer research. Our uniquely personal approach to our clients’ specific needs recognizes that the goals of different companies of various sizes and in different stages are not the same.  Our focus on providing clinically recapitulative models comes with significant experience and validation data in including co-modeling of clinical chemo/radio/immunotherapy standards of care as benchmarks or as combination therapies with new potential therapeutics.


Subscribe to RSS - Oncology